Immune Patterns Shape Liver Hepatocellular Carcinoma Prognosis

Area of Science:

• Hepatocellular carcinoma (LIHC) research
• Immunotherapy and tumor microenvironment
• Cancer genomics and bioinformatics

Background:

• Immune cell infiltration (ICI) and tumor genetic variability significantly influence liver hepatocellular carcinoma (LIHC) prognosis and treatment.
• Understanding the interplay between the tumor immune microenvironment (TIME) and genetic landscape is crucial for improving LIHC outcomes.
• Current knowledge on the specific roles of these factors in LIHC progression and immunotherapy response requires further elucidation.

Purpose of the Study:

• To investigate how immune cell infiltration and genetic factors shape LIHC progression.
• To identify key regulatory genes that can potentially enhance the effectiveness of immunotherapy in LIHC.
• To explore the prognostic value of tumor mutational burden (TMB) and specific immune infiltration patterns in LIHC.

Main Methods:

• Analysis of LIHC datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).
• Application of CIBERSORT and ESTIMATE algorithms for tumor immune microenvironment (TIME) evaluation and tumor mutational burden (TMB) calculation.
• Utilized gene set enrichment analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning to identify immunoregulatory genes, including CST7, with validation in mouse models for PD-1 blockade response.

Main Results:

• Distinct clusters of immune cell infiltration (ICI) associated with survival were identified, with Cluster B patients exhibiting significantly better outcomes.
• Gene subtype A correlated with prolonged survival and increased M1 macrophage infiltration.
• CST7 was identified as a critical regulator promoting CD8+ T cell infiltration and showing synergistic effects with PD-1 antibody therapy. TMB was a significant independent prognostic marker.

Conclusions:

• CST7 plays a vital role in enhancing immune cell infiltration (ICI) within the tumor microenvironment.
• CST7 significantly boosts the efficacy of PD-1 based immunotherapy in hepatocellular carcinoma (LIHC).
• CST7 represents a promising therapeutic target for improving immunotherapy outcomes in LIHC patients.